Can Berberine Support Hormonal Balance In Women With PCOS?

Polycystic ovary syndrome (PCOS) affects an estimated 6–13% of reproductive-age women globally, making it the most common endocrine disorder in this population. While historically framed as a reproductive condition, contemporary understanding places insulin resistance at its mechanistic core.

PCOS is diagnosed by some combination of irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. The condition exists on a spectrum and presents differently across individuals.

The majority of women with PCOS show measurable insulin resistance independent of body weight. Elevated insulin stimulates ovarian androgen production and reduces hepatic sex-hormone-binding globulin synthesis, increasing free testosterone. This drives many of the visible symptoms of the condition.

The downstream consequences of insulin-driven hyperandrogenism include anovulation, irregular menstrual cycles, acne, hirsutism and metabolic complications including elevated risk of type 2 diabetes later in life. Addressing insulin resistance therefore addresses the upstream driver of multiple symptom clusters simultaneously.

Several randomised trials have examined berberine in women with PCOS. Reported outcomes include reductions in fasting insulin, HOMA-IR, total testosterone and waist-to-hip ratio, with improvements in lipid profile and, in some studies, menstrual regularity. Effect sizes are generally comparable to metformin, the most commonly prescribed pharmaceutical intervention for the metabolic dimension of PCOS.

Women considering berberine for PCOS should consult a clinician familiar with the condition. Berberine is not appropriate during pregnancy and may interact with oral contraceptives and other prescription medications.